Atara Biotherapeutics Stock News

FUJIFILM (FUJIY) is acquiring a cell therapy manufacturing facility from Atara Biotherapeutics (ATRA) for $100M.The Thousand Oaks, Calif.-based facility has the flexibility to produce

Atara Biotherapeutics Inc (ATRA) shares closed today 12.9% higher than it did at the end of yesterday. The stock is currently up 2.0% year-to-date, down 13.6% over the past 12 months, and up 8.6% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $16.23 and as low as $13.93 this week.Shares closed 26.5% below its 52-week high and 36.1% above its 52-week low.Trading volume this week was 33.5% lower than the 10-day average and 31.1% lower than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -130.5% The company's stock price performance over the past 12 months beats the peer average by -71.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Atara Biotherapeutics Inc (ATRA) shares closed today 12.9% higher than it did at the end of yesterday. The stock is currently up 2.0% year-to-date, down 14.7% over the past 12 months, and up 8.6% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $16.23 and as low as $13.93 this week.Shares closed 26.5% below its 52-week high and 36.1% above its 52-week low.Trading volume this week was 34.6% lower than the 10-day average and 36.1% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -117.2% The company's stock price performance over the past 12 months beats the peer average by -52.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to

Atara Biotherapeutics <> announced a multi-year extension for its collaboration with Be The Match BioTherapies to source healthy donor cells for the off-the-shelf T-cell

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to

Atara Biotherapeutics Inc. (NASDAQ:ATRA) shares, rose in value on Friday, 12/17/21, with the stock price down by -0.79% to the previous days close as strong demand from buyers drove the stock to $15.15. Actively observing the price movement in the last trading, the stock closed the session at $15.27, falling within a range of $14.77 Read This First Before You Buy Atara Biotherapeutics Inc. (NASDAQ: ATRA) Stock Read More »

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) gapped up prior to trading on Tuesday . The stock had previously closed at $15.66, but opened at $16.99. Atara Biotherapeutics shares last traded at $15.57, with a volume of 546 shares trading hands. A number of research firms have recently commented on ATRA. Mizuho began coverage on shares of Atara […]

NEW YORK , Dec. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KPLT, ATRA, CLSK, LICY, and LCID. Full story available on Benzinga.com

Atara Biotherapeutics Inc (NASDAQ: ATRA ) posted efficacy and safety results from its Phase 3 ALLELE study of tabelecleucel (tab-cel) for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). EBV+ PTLD is a rare complication after a solid organ (SOT) or hematopoietic stem cell transplant (HSCT). The overall response rate was 50% in both the SOT and HCT groups. 26.3% of patients overall achieved a complete response, and just under 23.7% reached a partial response. Eleven of … Full story available on Benzinga.com